Englander Institute for Precision Medicine

A mitochondrial checkpoint to adaptive anticancer immunity.

TitleA mitochondrial checkpoint to adaptive anticancer immunity.
Publication TypeJournal Article
Year of Publication2023
AuthorsKepp O, Liu P, Kroemer G, Galluzzi L
JournalOncoimmunology
Volume12
Issue1
Pagination2271693
Date Published2023
ISSN2162-402X
KeywordsProto-Oncogene Proteins c-bcl-2
Abstract

BCL2 robustly preserves mitochondrial integrity, hence inhibiting innate immune signaling and apoptotic cell death in several cell types. Here, we comment on our recent data demonstrating that BCL2 also limits the ability of dendritic cells to elicit adaptive immune responses, lending support to a universal immunosuppressive function for the mitochondrial immune checkpoint.

DOI10.1080/2162402X.2023.2271693
Alternate JournalOncoimmunology
PubMed ID37860277
PubMed Central IDPMC10583618
Grant ListR01 CA271915 / CA / NCI NIH HHS / United States
U54 CA274291 / CA / NCI NIH HHS / United States

Weill Cornell Medicine Englander Institute for Precision Medicine 413 E 69th Street
Belfer Research Building
New York, NY 10021